Suppr超能文献

中国先天性高胰岛素血症自发缓解患儿的临床及遗传学特征分析

Analysis of clinical and genetic characteristics of Chinese children with congenital hyperinsulinemia that is spontaneously relieved.

机构信息

Department of Endocrinology, Genetics and Metabolism, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, 100045, Beijing, China.

Department of Pediatrics, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China.

出版信息

Endocrine. 2021 Apr;72(1):116-123. doi: 10.1007/s12020-020-02585-x. Epub 2021 Jan 27.

Abstract

OBJECTIVE

This study aimed to analyze the clinical and genetic characteristics of Chinese children with congenital hyperinsulinemia (CHI) that is spontaneously relieved.

METHODS

The patient group comprised 200 children with CHI that were treated at the Beijing Children's Hospital from January 2006 to December 2018. The patients were divided into two groups according to their prognosis: the spontaneous remission group (n = 92) and the nonspontaneous remission group (n = 108). The clinical characteristics, pathogenic genes, diagnosis and treatment process, and follow-up data of both groups were analyzed retrospectively.

RESULTS

Of the 200 children with CHI, 92 achieved spontaneous remission. The age of spontaneous remission was between one month and nine years, and 47 of the children were relieved before the age of one year. The median age of onset was 85 days (range: 1-2825 days) in the spontaneous remission group and 2 days (range: 1-210 days) in the nonspontaneous remission group (P < 0.05). The mean birth weight was 3.44 ± 0.76 kg for the spontaneous remission group and 3.95 ± 0.75 kg for the nonspontaneous remission group (P < 0.05). Of the 92 children in the spontaneous remission group, 65 were treated with diazoxide with effective rate of 81.5% (53/65). In 12 cases in which diazoxide treatment failed, octreotide was used with an effective rate of 83.3% (10/12). Of the 108 children in the nonspontaneous remission group, 88 were treated with diazoxide with an effective rate of 43.2 % (38/88), and 29 children were treated with octreotide with an effective rate of 48.28% (14/29). Of the 30 children in the spontaneous remission group that underwent mutation analysis of CHI-related pathogenic genes, 10 children (10/30, 33.3%) carried mutations. Of the 48 children in the nonspontaneous remission group that underwent mutation analysis of CHI-related pathogenic genes, 37 children (37/48, 77.1%) were found to carry mutations. All of the differences in the indices mentioned above were statistically significant.

CONCLUSIONS

The rate of spontaneous remission of CHI was significantly higher in children with late age of CHI onset, light birth weight, effective diazoxide treatment, and no common pathogenic gene mutations. Spontaneous remission was also possible for a small number of children that carried mutations in the ABCC and KCNJ11 genes and in whom diazoxide treatment failed.

摘要

目的

本研究旨在分析中国自发性缓解的先天性高胰岛素血症(CHI)患儿的临床和遗传特征。

方法

患者组包括 200 例 2006 年 1 月至 2018 年 12 月在北京儿童医院接受治疗的 CHI 患儿。根据预后将患者分为两组:自发性缓解组(n=92)和非自发性缓解组(n=108)。回顾性分析两组患儿的临床特征、致病基因、诊断和治疗过程及随访资料。

结果

200 例 CHI 患儿中,92 例实现自发性缓解。自发性缓解的年龄为 1 个月至 9 岁,47 例患儿在 1 岁前缓解。自发性缓解组的发病中位年龄为 85 天(范围:1-2825 天),而非自发性缓解组为 2 天(范围:1-210 天)(P<0.05)。自发性缓解组患儿的平均出生体重为 3.44±0.76kg,而非自发性缓解组为 3.95±0.75kg(P<0.05)。在 92 例自发性缓解组患儿中,65 例接受二氮嗪治疗,有效率为 81.5%(53/65)。在 12 例二氮嗪治疗失败的病例中,使用奥曲肽治疗的有效率为 83.3%(10/12)。在 108 例非自发性缓解组患儿中,88 例接受二氮嗪治疗,有效率为 43.2%(38/88),29 例接受奥曲肽治疗,有效率为 48.28%(14/29)。在 30 例自发性缓解组患儿中,对 CHI 相关致病基因进行突变分析,10 例(10/30,33.3%)患儿携带突变。在 48 例非自发性缓解组患儿中,对 CHI 相关致病基因进行突变分析,37 例(37/48,77.1%)患儿携带突变。上述所有指标的差异均有统计学意义。

结论

CHI 发病年龄晚、出生体重轻、二氮嗪治疗有效且无常见致病基因突变的患儿,CHI 自发性缓解率显著较高。少数携带 ABCC 和 KCNJ11 基因突变且二氮嗪治疗失败的患儿也可能自发缓解。

相似文献

2
Clinical Management and Gene Mutation Analysis of Children with Congenital Hyperinsulinism in South China.
J Clin Res Pediatr Endocrinol. 2019 Nov 22;11(4):400-409. doi: 10.4274/jcrpe.galenos.2019.2019.0046. Epub 2019 Jun 18.
4
Clinical and laboratory evaluation of children with congenital hyperinsulinism: a single center experience.
J Pediatr Endocrinol Metab. 2022 Nov 22;36(1):53-57. doi: 10.1515/jpem-2022-0155. Print 2023 Jan 27.
6
ABCC8 and KCNJ11 molecular spectrum of 109 patients with diazoxide-unresponsive congenital hyperinsulinism.
J Med Genet. 2010 Nov;47(11):752-9. doi: 10.1136/jmg.2009.075416. Epub 2010 Aug 3.
8
Congenital hyperinsulinism due to compound heterozygous mutations in ABCC8 responsive to diazoxide therapy.
J Pediatr Endocrinol Metab. 2020 May 26;33(5):671-674. doi: 10.1515/jpem-2019-0457.
10
Evaluation and management of neonatal onset hyperinsulinemic hypoglycemia: a single neonatal center experience.
J Matern Fetal Neonatal Med. 2023 Dec;36(2):2272014. doi: 10.1080/14767058.2023.2272014. Epub 2023 Oct 20.

引用本文的文献

1
IMPACT OF ABCC8 AND TRPM4 GENETIC VARIATION IN CENTRAL NERVOUS SYSTEM DYSFUNCTION ASSOCIATED WITH PEDIATRIC SEPSIS.
Shock. 2024 Nov 1;62(5):688-697. doi: 10.1097/SHK.0000000000002457. Epub 2024 Sep 3.
2
A loss-of-function mutation in KCNJ11 causing sulfonylurea-sensitive diabetes in early adult life.
Diabetologia. 2024 May;67(5):940-951. doi: 10.1007/s00125-024-06103-w. Epub 2024 Feb 17.
3
Genotype-phenotype correlation in Taiwanese children with diazoxide-unresponsive congenital hyperinsulinism.
Front Endocrinol (Lausanne). 2023 Nov 16;14:1283907. doi: 10.3389/fendo.2023.1283907. eCollection 2023.
4
Innovation in Hyperinsulinemia Diagnostics with ANN-L() Models.
Diagnostics (Basel). 2023 Feb 20;13(4):798. doi: 10.3390/diagnostics13040798.

本文引用的文献

1
Determination of insulin for the diagnosis of hyperinsulinemic hypoglycemia.
Best Pract Res Clin Endocrinol Metab. 2013 Dec;27(6):763-9. doi: 10.1016/j.beem.2013.06.005. Epub 2013 Jul 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验